

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **Swang Chai Chuan Limited**

**雙財莊有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2321)**

### **VOLUNTARY ANNOUNCEMENT JOINT VENTURE IN RELATION TO OVINE NANO-COLLAGEN PRODUCTION FACILITY**

This announcement is made by Swang Chai Chuan Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Company has entered into a binding joint venture agreement (the “**JV Agreement**”) with Holista Colltech Limited (“**HCT**”) in relation to the funding, development and operation of an ovine nano-collagen production facility in Collie, Western Australia.

The joint venture will be undertaken through Ovicoll Pty Ltd (the “**JV Company**”), with an initial shareholding structure of 50:50 between the Company and HCT. The Company will contribute RM5,000,000 (approximately AUD1.6 million) as its initial capital contribution to fund the commissioning and initial working capital requirements of the JV Company.

As part of the commercial arrangement, HCT has agreed to make payments equivalent to 3% per annum on the Company’s initial capital contribution for a period of two years.

HCT retains a contractual option to increase its interest in the JV Company to 75%, exercisable between the second and fifth anniversaries of the Company’s initial capital contribution, subject to the terms of the JV Agreement.

In connection with the joint venture, a substantial shareholder of HCT has provided a personal guarantee in favour of the Company in respect of certain financial obligations of the JV Company.

The board of the directors of the JV Company will comprise an equal number of directors nominated by the Company and HCT. HCT will be responsible for the day-to-day management and operation of the JV Company whereas the Company will participate in the governance of the JV Company through board representation and approval rights over key strategic and financial matters.

HCT will retain ownership of all pre-existing and newly developed intellectual property relating to the ovine nano-collagen technology, with the JV Company being granted a licence to utilise such technology for its business.

## **INFORMATION ON THE PARTIES TO THE JV AGREEMENT**

The Company is a company incorporated in Cayman Islands with limited liability and is an investment holding company which, through its subsidiaries, is principally engaged in Fast-Moving Consumer Goods (FMCG) sales and distribution of food, beverages, household consumer products and provision of logistics, warehousing and other services in Malaysia. Holista Colltech Limited (ASX: HCT) is a Perth-based innovator in health and wellness solutions and whose shares are listed on the Australian Securities Exchange. HCT together with its controlled entities operate across four core business divisions: Dietary Supplements, Healthy Food Ingredients, Ovine Collagen, and Infection Control Solutions.

To the best of the Directors' knowledge, information and belief having made all reasonable enquiries, HCT and its ultimate beneficial owner(s) are independent of and not connected with the Company and its connected persons (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")) of the Company as at the date of this announcement. The entering into the JV Agreement and the transactions contemplated thereunder do not constitute a notifiable transaction of the Company under Chapter 14 of the Listing Rules.

## **BENEFITS OF AND REASONS FOR ENTERING INTO THE JV AGREEMENT**

The Board believes that the joint venture represents an opportunity for the Group to participate the development and commercialisation of ovine nano-collagen products, which have applications in nutraceutical, food, cosmetic and biomedical sectors.

The Company's participation as an equity partner is expected to support the commercialisation and regional expansion of collagen products, including opportunities in halal-compliant markets.

The terms of the JV Agreement were negotiated between the parties thereto after arm's length negotiations. In light of the above, the Board is of the view that the terms of the JV Agreement are fair and reasonable and in the interests of the Company and its shareholders as a whole.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Swang Chai Chuan Limited**  
**Soon See Beng**  
*Chairman and Chief Executive Officer*

Hong Kong, 5 May 2026

*As at the date of this announcement, the Executive Directors are Mr. Soon See Beng, Mr. Soon Chiew Ang and Mr. Soon See Long; and the Independent Non-executive Directors are Mr. Lee Teck Hoe, Datuk Tan Teow Choon, Mr. Lum Kan Fai and Ms. Saw Chooi Lee.*